Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND-CABG: MC-1 in High-Risk CABG Surgery
NCT00157716Phase 2Completed
- Sponsor
- Medicure Inc.
- Start
- Apr 2004
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of pyridoxal-5'-phosphate in reperfusion injury (IRI) and Myocardial ischemia (MI) (3 arms), sponsored by Medicure Inc. Primary endpoint: Combined incidence of cardiovascular death, nonfatal myocardial infarction and nonfatal cerebral infarction at 30 days. Started Apr 2004; status: completed.
02
Drugs
pyridoxal-5'-phosphate
03
Conditions
reperfusion injury (IRI)Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT00157716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157716.